Dow Up1.63% Nasdaq Up0.97%

Franklin Biotechnology Discovery R6 (FRBRX)

153.75 Up 1.43(0.94%) Oct 17

Profile as of Sep 29, 2014Get Profile for:
Franklin Biotechnology Discovery R6
Franklin Strategic SeriesOne Franklin ParkwaySan Mateo, CA 94403-1906
Map
Phone: 800-632-2301
Fund Overview 
Category:Health
Fund Family:Franklin Templeton Investments
Net Assets:1.56B
Year-to-Date Return:20.63%
Yield:0.00%
Morningstar Rating:4 stars
Fund Inception Date:May 1, 2013
Morningstar Style Box 
Health
[View Category Definition]
View Top Health Funds
About the Morningstar Style Box
Management Information 
Evan S. McCulloch
Lead Manager since Sep 15, 1997
Mr. McCulloch has been a portfolio manager of the Fund since 1997 and assumed duties of lead portfolio manager of the Fund in 2000. He has primary responsibility for the investments of the Fund. He has final authority over all aspects of the Fund's investment portfolio, including but not limited to, purchases and sales of individual securities, portfolio risk assessment, and the management of daily cash balances in accordance with anticipated cash management requirements. The degree to which he may perform these functions, and the nature of these functions, may change from time to time.
Investment Information 
Min Initial Investment:1,000,000
Min Initial Investment, IRA:N/A
Min Initial Investment, AIP:N/A
Min Subsequent Investment:N/A
Min Subsequent Investment, IRA:N/A
Min Subsequent Investment, AIP:N/A
FRBRX can be purchased from 6 brokerages.

Fund Summary 
The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. It predominantly invests in equity securities, primarily common stock. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of foreign or U.S. issuer. It is non-diversified.

Fund Operations 
Last Dividend : 0.00
Last Cap Gain (Dec 15, 2013) : 0.00
Annual Holdings Turnover (Oct 15, 2014) : 48.70%
Average for Category:52.61%
Fees & Expenses 
ExpenseFRBRXCategory Avg
Annual Report Expense Ratio (net):0.63%1.39%
Prospectus Net Expense Ratio:0.63%N/A
Prospectus Gross Expense Ratio:0.63%N/A
Max 12b1 Fee:N/AN/A
Max Front End Sales Load:N/A5.28%
Max Deferred Sales Load: N/A2.37%
3 Yr Expense Projection*:202668
5 Yr Expense Projection*:3511,044
10 Yr Expense Projection*:7862,042
* Per $10,000 invested